CHILDHOOD SYMPTOMS ASSOCIATED WITH CHRONIC WIDESPREAD PAIN IN ADULTHOOD an epidemiological view. Best Pract Res Clin Rheumatol 1999;13: 403–14. 32. Jones GT, Silman AJ, Macfarlane GJ. Parental pain is not associated with pain in the child: a population based study. Ann Rheum Dis 2004;63:1152–4. 33. Macfarlane GJ, Croft PR, Schollum J, Silman AJ. Widespread pain: is an improved classification possible? J Rheumatol 1996;23:1628–32. 34. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ. The association between chronic widespread pain and mental disorder: a population-based study. Arthritis Rheum 2000;43:561–7. 35. Wigers SH. Fibromyalgia outcome: the predictive value of symptom duration, physical activity, disability pension, and critical life events;—a 4.5 year prospective study. J Psychosom Res 1996;41: 235–43. Errata DOI 10.1002/art.22729 In the article by York et al published in the March 2007 issue of Arthritis & Rheumatism (pp. 1010–1020), the panels of Figure 1 are referred to incorrectly in the legend, because the figure was published in the wrong orientation. The corrected legend (panels corresponding to the way the figure was actually published) is as follows: “Cluster of interferon (IFN)–regulated genes expressed by peripheral blood mononuclear cells in a subset of patients with systemic sclerosis (SSc) and healthy control subjects. Genes were clustered by unsupervised, hierarchic clustering after selection of genes that were expressed a mean 1.5-fold higher in SSc patients compared with healthy subjects and after filtering out genes with a mean expression value ⱕ50. The top right panel shows a section of the hierarchic clustering (mostly duplicated in the top left panel), and the bottom panels show expanded IFN-regulated gene clusters (expanded areas boxed in yellow in top panels). Color variations from lighter to darker shades of blue represent levels of gene expression from lower to higher, respectively. Gene names are listed below the panels, and asterisks denote genes that have been previously recognized as regulated by IFN. Siglec-1 (shown as sialoadhesin) is represented by 2 probe sets.” DOI 10.1002/art.22730 In the article by Westhovens et al published in the April 2006 issue of Arthritis & Rheumatism (pp. 1075–1086), there were several errors under the Dose Escalation heading in the Results section. The two paragraphs under that heading should have read as follows (corrections in italics): Of the 329 patients who entered the dose-escalation phase of the study, 100 patients (30.4%) received a dose escalation because they did not meet the criteria for response at week 22 or because they initially met the response criteria at week 22 but later met the criteria for a disease flare. Fifty-nine patients (17.9%) received 1 dose increase for a total of 4.5 mg/kg, 21 patients (6.4%) received 2 increases for a total dose of 6.0 mg/kg, 13 patients (4.0%) received 3 increases for a total of 7.5 mg/kg, 7 patients (2.1%) received 4 increases for a total dose of 9 mg/kg, the latter being the maximum allowed by the study protocol. Nine additional patients received dose escalation in error; i.e., they did not meet the criteria for lack of response or flare. Improved efficacy was observed in the patients in group 2 who received dose escalations (13). Nevertheless, patients in group 2 who continued to receive 3 mg/kg infliximab in combination with MTX had similar frequencies of infections, serious infections, or other adverse events compared with those who received dose escalations. Of the 109 patients in group 2 who received a dose escalation, 77 (71%) reported experiencing an adverse event, 14 (13%) reported experiencing a serious adverse event, 39 (36%) reported developing an infection, and 2 (2%) reported developing a serious infection between weeks 22 and 54. Of the 220 patients in group 2 who did not receive a dose escalation at any time, 160 (73%) reported experiencing an adverse event, 19 (9%) reported experiencing a serious adverse event, 80 (36%) reported developing an infection, and 5 (2%) reported developing a serious infection between baseline and week 54. The mean duration of treatment was 30.6 weeks for patients with a dose escalation and 31.0 weeks for patients without a dose escalation. The changes do not affect the overall conclusions of the study. We regret the errors. 1675
1/--страниц